Clinical trials are the foundation for future treatments. The MEVPRO clinical trial program is evaluating a study medicine given together with standard care, aiming to improve therapeutic options for metastatic prostate cancer. Participation not only aids in understanding this disease better but also contributes to hope through science.

Dr. Keith Crawford, PHEN’s Director of Clinical Trials and Patient Education, spoke with Dr. Neal Shore, Medical Director of the Carolina Urological Research Center. They discussed who may qualify, how often visits occur, common side effects, and why diverse participation is important.

Men with metastatic prostate cancer and their caregivers should view this session. They can learn how these clinical trials work, what to expect, and how to check eligibility with their care team.